Literature DB >> 7607852

Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity.

G Yosipovitch1, B Shohat, J Bshara, A Wysenbeek, A Weinberger.   

Abstract

Soluble interleukin 2 receptor (SIL-2R) and interleukin 1-B (IL-1B) levels in peripheral blood were assayed by enzyme-linked immunoabsorbent method in 25 patients with Behçet's disease and in 20 healthy controls. Eighteen patients suffered from active Behçet's disease and 6 patients had severe disease manifestations. SIL-2R levels were followed for a period of 16 months and were correlated with disease activity. In all the patients with Behçet's disease the levels of SIL-2R and IL-1B were significantly higher than their control, 958 +/- 712 vs. 404 +/- 119 u/ml (P < 0.001) for SIL-2R and 639 +/- 741 vs. 59 +/- 53 pg/ml (P < 0.001) for IL-1B. No correlation was found between disease activity and severity and the levels of SIL-2R and IL-1B. It is suggested that levels of SIL-2R and IL-1B are elevated in patients with Behçet's disease but do not serve as disease activity markers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607852

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  9 in total

1.  PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.

Authors:  Luca Cantarini; Antonio Vitale; Giulia Bersani; Laura Martin Nieves; Marco Cattalini; Giuseppe Lopalco; Francesco Caso; Luisa Costa; Florenzo Iannone; Giovanni Lapadula; Mauro Galeazzi; Angela Ceribelli; Enrico Brunetta; Carlo Selmi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2015-02-10       Impact factor: 2.980

Review 2.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

3.  Macrophage Migration Inhibitory Factor -173GC Variant Might Increase the Risk of Behçet's Disease.

Authors:  Ayse Feyda Nursal; Serbulent Yigit; Ercan Tural; Goknur Kalkan; Mehmet Kemal Tumer; Akin Tekcan
Journal:  Med Princ Pract       Date:  2018-04-18       Impact factor: 1.927

4.  Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease.

Authors:  Nurşen Düzgün; Ergin Ayaşlioğlu; Hüseyin Tutkak; Olcay T Aydintuğ
Journal:  Rheumatol Int       Date:  2003-11-05       Impact factor: 2.631

5.  Anakinra treatment in drug-resistant Behcet's disease: a case series.

Authors:  Luca Cantarini; Antonio Vitale; Perla Scalini; Charles A Dinarello; Donato Rigante; Rossella Franceschini; Gabriele Simonini; Giulia Borsari; Francesco Caso; Orso Maria Lucherini; Bruno Frediani; Ilaria Bertoldi; Leonardo Punzi; Mauro Galeazzi; Rolando Cimaz
Journal:  Clin Rheumatol       Date:  2013-12-05       Impact factor: 2.980

Review 6.  Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease.

Authors:  Marco Cattalini; Martina Soliani; Donato Rigante; Giuseppe Lopalco; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2015-08-18       Impact factor: 4.711

7.  New Insights into Behçet's Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation.

Authors:  Anna Santarsiero; Pietro Leccese; Paolo Convertini; Angela Padula; Paolo Abriola; Salvatore D'Angelo; Faustino Bisaccia; Vittoria Infantino
Journal:  Mediators Inflamm       Date:  2018-06-28       Impact factor: 4.711

8.  Saliva and Serum Cytokine Profiles During Oral Ulceration in Behçet's Disease.

Authors:  Tanya Novak; Mojgan Hamedi; Lesley Ann Bergmeier; Farida Fortune; Eleni Hagi-Pavli
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

9.  Behçet's Disease: Autoimmune or Autoinflammatory?

Authors:  Alireza Hedayatfar
Journal:  J Ophthalmic Vis Res       Date:  2013-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.